Hi {{first name | there}},

My birthday is this weekend. I spent part of Friday listening to an FDA committee vote on peptides, because apparently this is who I am now 😆.

More seriously, birthdays make me reflective. I am genuinely grateful for everything I have learned from this community of experts, and especially from my patients, who keep making me a better doctor.

For this next year, I have three non-work goals:

I have not signed up for dance class yet. I did, however, spend Friday on an FDA webcast. So: peptides.

By the end, six of seven peptide families had received a favorable recommendation. For the past year, I have been the person telling people that BPC-157 has more animal data than human data, that TB-500 borrows evidence from a related molecule, and that Epitalon's telomere story is nowhere near a serious longevity claim.

This is all still true.

Even so, I was glad. People already injecting these products should be able to go through a prescriber and a licensed pharmacy instead of a research-chemical website. Now FDA, pharmacies, and clinicians have to make that option safer than the gray market existing today.

The Pharmacy Compounding Advisory Committee recommended both the free-base and acetate forms of BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax for possible inclusion on the 503A Bulks List. Emideltide, also called DSIP, was the only peptide that lost. I put the full tally here.

This recommendation is still only advisory. No peptide was approved by the FDA, no pharmacy got new permissions, and nothing became newly available on Friday.

However, you can expect some interesting developments over the next few months...

I gave you the full evidence ladder in The Peptide Gray Zone, so I am not going to repeat the entire tour. Here is the commercial shorthand behind this vote:

That is the market. The figure below shows the much narrower uses attached to FDA's ballot. Neither column is a list of proven benefits, and Friday's vote did not turn either one into evidence.

If you read the tally as a ranking of clinical evidence, the result makes no sense.

Emideltide had two tiny double-blind studies in chronic insomnia. One 1987 trial included fourteen patients. A 1992 randomized trial included sixteen and found weak effects. Old, small, discouraging work, but human experiments nonetheless.

Epitalon had no convincing controlled human insomnia trial.

Emideltide lost, six to seven. Epitalon passed, seven to four.

That does not prove the committee punished evidence. It shows that members were deciding whether regulated compounding was preferable to continued gray-market demand. FDA's scientific staff had recommended no on all seven families because the evidence, characterization, and safety records were too thin. Several yes-voters said the alternative was pushing people toward products with even less accountability.

Last month I covered the research-vial problem, the missing sterility and sourcing information, and the questions you should ask before injecting a peptide.

It turns out the majority of the committee accepted a harm-reduction argument: demand already exists, and a prescription plus a licensed pharmacy gives us a named patient, a documented dose, a label, a lot number, a chart, and someone accountable. It does not prove that a molecule works for its intended (or marketed) purpose. It gives an investigation somewhere to begin if something goes wrong.

The panel's composition deserves scrutiny. The Associated Press found peptide, compounding, or adjacent business ties among more than half a dozen members. The Washington Post reported that FDA officials had questioned whether some ties should disqualify people. But FDA says the members cleared ethics review.

The Las Vegas incident shown above was reported by ProPublica. Investigators did not establish a cause.

Today: nothing is newly legal, available, or approved. Pharmacies cannot start filling BPC-157 prescriptions because of the vote.

Next: FDA reviews the committee record and decides whether to act on the recommendations. The committee cannot put a substance on the Bulks List by itself.

If FDA proceeds: the agency would normally publish a proposed rule, open a public-comment period, review the record, and then issue a final rule. Regulatory attorneys at Orrick estimate that this process typically takes 12–24 months. FDA has not promised that timeline. It could move faster, move slower, decline some recommendations, or use an interim enforcement approach.

Only after a favorable final action: an eligible 503A pharmacy could legally compound the exact listed substance for an individual patient with a valid prescription, subject to the listing language and other federal and state law. The finished drug would remain unapproved. This would not automatically authorize 503B office stock, every route, every chemical form, or national telehealth access.

FDA says it will hold another advisory meeting before the end of February 2027. The exact date and location are still pending. FDA says a Federal Register notice and public-comment docket are coming, with meeting materials and a webcast posted no later than two business days before the meeting. The announced substances are:

These five still have to go through evidence review, a committee vote, FDA action, and any required rulemaking.

The July vote did not authorize 503A pharmacies to fill these six families. Pharmacies can map exact chemical forms, routes, state-law constraints, API-supplier diligence, sterility testing, labeling, adverse-event workflows, and what they would need if a final rule is favorable. They should not treat a committee vote as inventory authorization.

Do not build the February menu yet. Inventory, supplier contracts, patient menus, and revenue forecasts should not assume that the five announced substances will receive favorable votes or final listings. Any current GHK-Cu plan needs a written, route-specific legal analysis because non-injectable and injectable products do not share the same interim posture.

503B facilities did not get an office-stock pathway. The July recommendation concerned the 503A Bulks List. A clinic should not assume that a future 503A listing means it can buy bulk office stock or administer the same product under a different 503B framework.

Clinics have months to build the boring foundation. Evidence tiers, eligibility criteria, contraindications, consent, baseline measurements, follow-up, stop rules, and pharmacy contracts all take time. Building those now is reasonable. Selling a future peptide menu as if FDA already cleared it is not.

Marketing is more confusing than ever. Accurate: “An FDA advisory committee recommended possible inclusion on the 503A Bulks List.” Inaccurate: “FDA approved BPC-157,” “peptides are legal again,” “FDA says these work,” or “now available by prescription.”

“Research use only” is not a force field. In a March warning letter to Gram Peptides, FDA said the surrounding human-use claims outweighed “not intended for human consumption” disclaimers. Pairing that label with recovery, weight, tanning, cognition, dosing, or injection claims still creates enforcement risk.

The gray market does not disappear this summer. Research-chemical sellers still occupy the access gap because no lawful channel opened on Friday. If regulated access eventually arrives, their advantage narrows. The competition shifts from who can ship a vial to who can document quality, prescribe responsibly, follow the patient, and handle an adverse event.

Several members voted yes while asking for conditions: U.S.-sourced active ingredient, patient registries, mandatory adverse-event reporting, or route limits. The ballot created none of those.

FDA staff explained that current 503A law limits what the agency can require. FDA generally cannot force every state-licensed pharmacy to register with the agency, report every compounded substance, use domestic ingredient, submit mandatory adverse-event reports, or undergo routine federal surveillance inspections. Some of that would require Congress.

FDA can control one important variable in a future Bulks List entry: route or dosage form. Staff confirmed that if a listing does not name a restriction, the substance may be compounded by any route or dosage form.

That makes the proposed-rule language consequential. KPV cream and KPV injection are not the same safety proposition. Neither are topical GHK-Cu and an injectable “systemic repair” protocol.

I am glad the committee created a plausible path toward accountable access. I am not excited about waiting an additional 12–24 months. But if that is the process, pharmacies and clinics should use it to build something better than a prettier peptide storefront.

So conclusion? No peptide stack for my birthday. A dance class would probably do me more good 😂.

Keep learning,

Hillary Lin, MD

If your real question is whether a peptide might help fatigue, start here. I walk through what the evidence supports, what can go wrong, and what I would want clarified before anyone writes a prescription.

Watch Peptides and Hormones for Fatigue? | Subscribe to The Longevity Show

🥣 Breakfast protein did not build more muscle. A meta-analysis of seven randomized trials found no improvement in lean mass, grip strength, or lower-limb strength from morning protein in older adults. Total protein and resistance training still matter; timing theater may not.

🫁 AI closed a real care gap: lung-nodule follow-up rose from 53.5% to 67.9%. The emergency-department workflow also raised patient notification from 75.0% to 88.4%. It was a retrospective pre/post study, so we still do not know whether it improved cancer outcomes.

🧠 A Parkinson's toolkit cut unplanned-care costs even though the primary quality-of-life endpoint missed. In a randomized trial, activities of daily living improved modestly and 12-month health and social-care costs fell, mainly through fewer unplanned admissions.

🧬 Parkinson's trials are getting a biological enrollment tool. FDA issued a Letter of Support for the cerebrospinal-fluid α-synuclein seed-amplification assay in synucleinopathy trials. That is trial infrastructure, not a routine screening test.

💉 GLP-1s took 6.47 kg off antipsychotic-associated weight gain. A meta-analysis of eight randomized trials in people with schizophrenia also found smaller waist circumference and HbA1c, with more gastrointestinal side effects.

🫀 The new cholesterol guideline adds millions of lower-risk adults to the statin conversation. A JAMA analysis estimated 21.5 million newly eligible U.S. adults, with a mean 10-year ASCVD risk of 3.1% in that group. At lower baseline risk, ApoB, family history, competing risks, and patient preference carry more of the decision.

Science of Skin Summit, September 17–20, Austin, TX. Speaking on AI in dermatology and skin and hair as windows into biological age.

MVMNT Longevity Summit, September 22–23, Coronado, CA. Leading a session on turning longevity data into clinical action.

Livelong Women's Health Summit, September 25–26, Hilton Midtown, New York City. Joining the expert faculty on AI-driven personalized medicine.

Science of Skin Longevity Summit, February 19–21, 2027, Scottsdale, AZ. Speaking on AI in precision diagnostics and joining the peptides panel.

A few reader-supported partners:

If you want physician-guided biological age testing, start on the testing page. It includes epigenetic age testing with consultation, plus organ-specific proteomic and SystemAge assessments when they fit the clinical question.

Have a question or topic you want covered? Reply to this email.

Was this forwarded to you? Subscribe here to get The Longevity Letter in your inbox.